Anti-PD-1 therapy curbs the expression of PD-L1 through either eliminating the tumor cells that overexpress PD-L1 and possess a hypomethylated PD-L1 promoter or switching off the PD-L1 expression through epigenetic modulation, therefore leading to resistance [67]. This evidence concerns the gene CD274 and neoplasm.